Akero Therapeutics (AKRO) Stock Overview
Engages in the development of treatments for patients with serious metabolic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AKRO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Akero Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.73 |
| 52 Week High | US$58.40 |
| 52 Week Low | US$21.34 |
| Beta | -0.28 |
| 1 Month Change | -3.39% |
| 3 Month Change | -9.46% |
| 1 Year Change | 71.80% |
| 3 Year Change | 268.82% |
| 5 Year Change | 44.50% |
| Change since IPO | 155.08% |
Recent News & Updates
Recent updates
Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments
May 21Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock
Apr 06Some Good MASH/NASH News From Akero Therapeutics
Jan 28Akero Therapeutics: Where This Potential MASH Play Stands Currently
Dec 31Akero Therapeutics: Good Candidate For The MASH Basket
Sep 20Akero Therapeutics' EFX Data Warrants Caution
Apr 03Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program
Mar 04Shareholder Returns
| AKRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | -0.4% | 0.5% |
| 1Y | 71.8% | -9.9% | 15.7% |
Return vs Industry: AKRO exceeded the US Biotechs industry which returned -9.9% over the past year.
Return vs Market: AKRO exceeded the US Market which returned 15.7% over the past year.
Price Volatility
| AKRO volatility | |
|---|---|
| AKRO Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AKRO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AKRO's weekly volatility has decreased from 16% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 67 | Andrew Cheng | akerotx.com |
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
Akero Therapeutics, Inc. Fundamentals Summary
| AKRO fundamental statistics | |
|---|---|
| Market cap | US$3.74b |
| Earnings (TTM) | -US$283.96m |
| Revenue (TTM) | n/a |
Is AKRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKRO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$283.96m |
| Earnings | -US$283.96m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.55 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.5% |
How did AKRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/01 14:45 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akero Therapeutics, Inc. is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Alexandria Hammond | BofA Global Research |
| Edward Nash | Canaccord Genuity |